li001

Study Finds Metabolic Weak Spot That Could Boost Cancer Treatment

Research Advances /

Researchers have found that disrupting a metabolic process called lipoylation can make cancer cells more vulnerable to certain treatments. The study shows that the enzyme LIPT1 links cell metabolism to DNA stability. When LIPT1 is blocked, a substance called 2-hydroxyglutarate builds up, causing DNA to become overly compacted. This slows DNA copying and leads to […]

Study Finds Metabolic Weak Spot That Could Boost Cancer Treatment Read More »

New Blood Test Using Nanotechnology Detects Pancreatic Cancer with 97% Accuracy

Diagnostics /

Scientists have developed a new blood test that uses nanotechnology and electrical signals to detect pancreatic cancer with high accuracy. Led by Stuart Ibsen, the test uses a microchip that applies a small electric charge to blood samples to capture tumor-derived nanoparticles. These particles are then labeled to identify cancer-specific biomarkers. In a blinded study, the

New Blood Test Using Nanotechnology Detects Pancreatic Cancer with 97% Accuracy Read More »

FDA Grants Expanded Access to Daraxonrasib After Promising Pancreatic Cancer Trial Results

Drug Approvals /

The U.S. Food and Drug Administration has authorized an expanded access program for daraxonrasib, an experimental treatment for patients with previously treated metastatic pancreatic cancer. The decision follows strong results from the Phase 3 RASolute 302 trial. The study showed that daraxonrasib significantly improved survival compared with standard chemotherapy. The drug reduced the risk of

FDA Grants Expanded Access to Daraxonrasib After Promising Pancreatic Cancer Trial Results Read More »

Real-World Study Confirms Nivolumab–Cabozantinib Combo Effective in Advanced Kidney Cancer

Treatment /

Final results show that the combination of nivolumab and cabozantinib remains highly effective for patients with advanced renal cell carcinoma in real-world settings. The study reported strong outcomes, with a 74% overall survival rate at 18 months. Patients had a median progression-free survival of 14 months, and the overall response rate reached 62.1%, with disease

Real-World Study Confirms Nivolumab–Cabozantinib Combo Effective in Advanced Kidney Cancer Read More »

FDA Approves Vepdegestrant for ESR1-Mutated Advanced Breast Cancer

Drug Approvals /

The U.S. Food and Drug Administration has approved vepdegestrant for adults with advanced or metastatic ER-positive, HER2-negative breast cancer that carries ESR1 mutations, after the disease has progressed on prior endocrine therapy. The approval is based on results from the Phase 3 VERITAC-2 trial, which compared vepdegestrant with fulvestrant. In patients with ESR1 mutations, the

FDA Approves Vepdegestrant for ESR1-Mutated Advanced Breast Cancer Read More »

New Study Explores Possible Link Between Pesticides and Early-Onset Colorectal Cancer

Research Advances /

Researchers say new technology could help uncover how environmental chemicals may be linked to rising cases of early-onset colorectal cancer, but they caution that current findings are still uncertain. A study published in Nature Medicine found a possible association between the herbicide picloram and colorectal cancer in younger adults. The research used molecular fingerprinting, an

New Study Explores Possible Link Between Pesticides and Early-Onset Colorectal Cancer Read More »

Study Identifies FLT1 Signaling Network as Key Driver of Kidney Cancer Progression and Drug Resistance

Research Advances /

A new study has identified FLT1 (VEGFR1) as a key driver of tumor growth in clear cell renal cell carcinoma. Researchers found that cancer cells release VEGFA, which activates FLT1 in nearby blood vessel cells, creating signals that promote tumor growth and weaken immune responses. This interaction triggers cellular senescence, where cells stop dividing but

Study Identifies FLT1 Signaling Network as Key Driver of Kidney Cancer Progression and Drug Resistance Read More »

Targeted ADC Ozuriftamab Vedotin Shows Promising Results in Advanced HPV-Related Throat Cancer

Targeted Therapy /

A new targeted therapy called ozuriftamab vedotin (Oz-V) is showing strong potential for patients with advanced HPV-related throat cancer who have already tried multiple treatments. This drug is a type of antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. What makes Oz-V unique is its ability to activate only in the acidic environment

Targeted ADC Ozuriftamab Vedotin Shows Promising Results in Advanced HPV-Related Throat Cancer Read More »

New Blood Test from Mayo Clinic Shows High Accuracy in Detecting Testicular Cancer

Diagnostics /

Researchers at the Mayo Clinic have developed a new blood test that could improve the detection of germ cell tumors, the most common type of testicular cancer. This method is designed to find cancers that are often missed by standard tumor marker tests. The study introduced two tools based on immune system signals. One test,

New Blood Test from Mayo Clinic Shows High Accuracy in Detecting Testicular Cancer Read More »

Ozekibart Combo Shows Promising Early Results in Heavily Pretreated Colorectal Cancer

Clinical Trails /

Early results from a Phase 1/2 clinical trial suggest that ozekibart (INBRX-109), a targeted antibody, may offer a new option for patients with advanced colorectal cancer who have already received multiple treatments. When combined with standard chemotherapy (FOLFIRI), the drug showed stronger activity than typically seen in late-stage settings. Among 45 patients, about 20% experienced

Ozekibart Combo Shows Promising Early Results in Heavily Pretreated Colorectal Cancer Read More »